Thrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19.

Matéria original

ABIFNA presente na reunião do GIPI
Anterior

ABIFNA presente na reunião do GIPI

Próxima

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19